RareResearch.AI
← Back to atlas

T663K

Category 3/4 — Most DruggableUncertain significanceLumenal · predictedσ-1 candidateSource card
ThreonineLysine at position 663 · C-terminal ER-lumenal (calcium binding, calmodulin, chaperone) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type T663 — polar contact to T665
Fullscreen ↗
DynaMut2 mutant · T663K
Mutant K663 — energy-minimized; 1 new contact formed
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

0 lost1 gained1 preserved
Interaction typeWild-type partnerMutant partnerStatus
Polar contactT665T665Preserved
Van der WaalsT665Gained

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
0.01kcal/mol
Stabilising — mild
AlphaMissense
0.747
likely pathogenic
AlphaFold pLDDT
79
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, single submitter
Associated conditions
Population frequency (gnomAD v4)Absent from gnomAD v4
cDNA changec.1988C>A
ClinVar accessionVCV003637011
Last evaluated2024/07/11 00:00

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Full Variant Card

WFS1 Wolframin — T663K Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Threonine → Lysine at position 663. C-terminal ER-lumenal (calcium binding. ClinVar Uncertain significance, AlphaMissense 0.747, DynaMut2 ΔΔG +0.01 kcal/mol (stabilising).


Identity

FieldValue
VariantT663K (p.Threonine663Lysine)
DNA changec.1988C>A
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV003637011
Amino acid changeThreonine (T) → Lysine (K)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 66379.00 — well-folded
DomainC-terminal ER-lumenal (calcium binding, calmodulin, chaperone)
Position contextC-terminal lumenal domain · position 663 projects into the ER lumen
IDR flagNo — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 663 sits in the C-terminal lumenal domain (residues 653–869), wolframin's largest soluble region. This domain projects into the ER lumen and is implicated in calcium handling, ER stress sensing, and protein–protein interactions with ATF6 and Na+/K+ ATPase β1. The wild-type residue is small polar (threonine — hydroxyl); the mutant is positively charged (lysine — primary amine). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.7469
am_classlikely pathogenic
InterpretationLikely pathogenic (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)0.01 (Stabilising)
Job ID178092121906
Result URLhttps://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092121906

Clinical Evidence

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, single submitter
Last evaluated2024/07/11 00:00
InheritanceInheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscapeT663K is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

(no conditions catalogued)


Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=0.01 < 2 kcal/mol (fold intact) + AlphaMissense 0.747 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.01 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.747. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • T663K_molstar_viewer.html — interactive 3D viewer (auto-highlights position 663 with ball-and-stick + neighbors within 5Å)
  • T663K_variant_card.md — this card (source of truth)
  • T663K_variant_card.html — styled printable card
  • T663K_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • T663K_wildtype_interactions.pse / T663K_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the T663K PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download T663K PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.